Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 3,701 matching trials from the live ClinicalTrials.gov search.
Conditions
Non Small Cell Lung Cancer
Interventions
DRP-104
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Conditions
Non-Small Cell Lung Carcinoma (NSCLC)
Interventions
Survey
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
15
States / cities
Duarte, California • Fort Wayne, Indiana • Goshen, Indiana + 9 more
Conditions
Non Small Cell Lung Cancer
Interventions
Entinostat, Erlotinib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 2 more
Conditions
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions
Bintrafusp Alfa, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Interventions
ALE.P02, Pembrolizumab
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Fullerton, California • Los Angeles, California + 5 more
Conditions
Non-small Cell Lung Cancer
Interventions
ZD1839, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions
Cofetuzumab Pelidotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Springdale, Arkansas • Stanford, California + 8 more
Conditions
Non-small Cell Lung Cancer
Interventions
carboplatin, paclitaxel, sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
27
States / cities
Los Angeles, California • Newark, Delaware • Wilmington, Delaware + 17 more
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
Conditions
Non-small Cell Lung Cancer
Interventions
Alectinib, Cobimetinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
C-TIL051
Biological
Lead sponsor
AbelZeta Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
New Orleans, Louisiana • Raleigh, North Carolina • Pittsburgh, Pennsylvania
Terminated No phase listed Observational

Bronchial Mapping (GCC 1635)

NCT02745548
Conditions
Thoracic Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Non-small Cell Lung Cancer
Interventions
Interviews
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
29
States / cities
Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions
PDR001, ACZ885, CJM112, TMT212, EGF816
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more
Conditions
Lung Cancer
Interventions
Bexarotene, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
gold sodium thiomalate, gene expression analysis, fluorine F 18 fluorothymidine, mass spectrometry, pharmacological study
Drug · Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Cognitive Assessment, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Biological · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Immune-related Colitis
Interventions
Methoxsalen, Infliximab, Vedolizumab
Drug
Lead sponsor
Therakos LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Non - Small Cell Lung Cancer NSCLC
Interventions
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
33
States / cities
Chandler, Arizona • Anaheim, California • Duarte, California + 29 more
Conditions
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Zilovertamab vedotin
Drug
Lead sponsor
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Hollywood, Florida • Orlando, Florida • Boston, Massachusetts + 5 more
Conditions
Metastatic Lung Cancer, Stage IV Lung Cancer
Interventions
Stereotactic Body Radiation Therapy, Pembrolizumab
Radiation · Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Malignant Lung Neoplasm, Metastatic Malignant Neoplasm in the Lung, Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer
Interventions
CAPP-Seq, Isovue-200, Computed Tomography Perfusion Imaging
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Palo Alto, California